161 related articles for article (PubMed ID: 11905608)
1. FDA licences imatinib mesylate for CML.
Habeck M
Lancet Oncol; 2002 Jan; 3(1):6. PubMed ID: 11905608
[No Abstract] [Full Text] [Related]
2. Is red tape stifling the progress of new anticancer drugs?
Lancet Oncol; 2002 Jan; 3(1):1. PubMed ID: 11905596
[No Abstract] [Full Text] [Related]
3. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
4. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
5. Drug developers unveil strategies aimed at imatinib-resistant CML.
Goozner M
J Natl Cancer Inst; 2010 May; 102(9):593-5. PubMed ID: 20421566
[No Abstract] [Full Text] [Related]
6. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
7. From the Food and Drug Administration.
Schwetz BA
JAMA; 2001 Jul; 286(1):35. PubMed ID: 11434814
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Druker BJ
Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592
[TBL] [Abstract][Full Text] [Related]
9. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
10. Selective effect of imatinib on serum IgM in a patient with CML.
Nagasawa M; Mizutani S
Int J Hematol; 2004 Nov; 80(4):381-2. PubMed ID: 15615266
[No Abstract] [Full Text] [Related]
11. Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Chrobák L; Voglová J
Acta Medica (Hradec Kralove); 2003; 46(3):85-9. PubMed ID: 14677715
[TBL] [Abstract][Full Text] [Related]
12. STI571 (glivec-tm): a new paradigm for the development of innovative therapies in onco-hematology?
Gambacorti C
Tumori; 2001; 87(6):S10-2. PubMed ID: 11989608
[No Abstract] [Full Text] [Related]
13. Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.
Cohen MH; Moses ML; Pazdur R
Oncologist; 2002; 7(5):390-2. PubMed ID: 12401900
[TBL] [Abstract][Full Text] [Related]
14. Effects of lower dose of imatinib to CML patients.
Horikoshi A; Takei K; Sawada S
Leuk Res; 2003 Dec; 27(12):1167. PubMed ID: 12921957
[No Abstract] [Full Text] [Related]
15. New strategies in controlling drug resistance in chronic myeloid leukemia.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
[TBL] [Abstract][Full Text] [Related]
16. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
17. Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
Anand M; Khorashad J; Marin D; Apperley JF; Goldman JM; Kaeda JS
Blood; 2006 Oct; 108(8):2881-2. PubMed ID: 17021308
[No Abstract] [Full Text] [Related]
18. Reduced dose imatinib mesylate therapy for chronic myeloid leukemia.
Zipin D; Savage DG
Leuk Lymphoma; 2004 Nov; 45(11):2363-4. PubMed ID: 15512833
[No Abstract] [Full Text] [Related]
19. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
